ClinicalTrials.gg
CompletedNCT02106130Updated Apr 8, 2014

A Drug Interaction Study of Mosapride and Rebamipide

A Phase 1 interventional study of Rebamipide and Mosapride citrate in Healthy, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-08.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

The investigators investigate the potential pharmacokinetic drug-drug interaction between Mosapride citrate 5 mg and Rebamipide 100 mg in healthy male volunteers who receive Mosapride citrate 5 mg, Rebamipide 100 mg, and both together in a 2 period repeatedly.

Read the detailed description

To evaluate the safety, drug-tolerance, pharmacokinetics of Mosapride citrate 5 mg or Rebamipide 100 mg monotherapy or Mosapride citrate 5 mg and Rebamipide 100 mg combination in healthy male subjects.

02

Conditions studied

  • Healthy

Keywords

  • Mosapride citrate
  • Rebamipide
  • pharmacokinetic drug drug interaction
  • oral administration
  • healthy male subjects
03

In context

Lead sponsor

IlDong Pharmaceutical Co Ltd is the lead sponsor of 50 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers, age 20 to 45 years
  2. Body weight ≥ 55kg (male), ≥ 50kg (female)
  3. Body weight index () 18.5 \~ 25
  4. Acceptable serum test, hematologic test, blood chemistry examination, urin test and , physical examination during screening
  5. Subject decided to participate voluntarily and gave written to comply with the instructions after listening to and fully understanding the detailed explanation about this trial.

Exclusion criteria

Exclusion Criteria:

  1. Subject has liver, kidney, neurologic, immunologic, respiratory, endocrine disease or hematologic·oncologic disease, cardiovascular disease or psychiatric disease (mood disorder, compulsive disorder etc.) or such medical history (including subject with hepatitis virus in case of liver disease).
  2. Subject has history of gastrointestinal disease (such as Crohn's disease, ulcer, acute or chronic pancreatitis etc.) or gastrointestinal surgery (except simple appendectomy or hernia operation) that can affect the absorption of the study drug.
  3. Subject has reaction to drug (aspirin, antibiotics, including study durgs, etc.) or history of clinically significant hypersensitivity reaction.
  4. Systolic blood pressure > 150mmHg or \<90mmHg, Diastolic blood pressure >100mmHg or \<50mmHg(Sitting blood pressure) during the screening procedure
  5. Subject has history of drug abuse or tested positive to abused drug in the urine drug screening test.
  6. For women, pregnant or breastfeeding woman or woman who was confirmed to be pregnant in the pregnancy test
  7. Subject takes caffeine-containing food 5 cups per day
  8. Subject continually drinks (in excess of 210g/week)
  9. Subject smokes 10 cigarettes or more in one day
  10. Subject took any prescribed drug or oriental medicine within 2 weeks prior to the first medication or any over-the-counter (OTC) drug within 1 week prior to the first medication (however, the subject can be included if other criteria are met according to the discretion of the investigator).
  11. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products within 30 days prior to the first dosing
  12. Subject participated in another study and received medication within 2 months prior to the first medication day.
  13. Subject received whole blood transfusion (500 mL) within 2 months prior to the first medication or blood transfusion within 1 month prior to the first medication.
  14. Subject was judged not to be eligible according to the discretion of the investigator for other reasons.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    R - R+M

    R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.

    Drug: Rebamipide · Drug: Mosapride citrate

  • Experimental
    R+M - R

    R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.

    Drug: Rebamipide · Drug: Mosapride citrate

  • Experimental
    M - R+M

    R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.

    Drug: Rebamipide · Drug: Mosapride citrate

  • Experimental
    R+M - M

    R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.

    Drug: Rebamipide · Drug: Mosapride citrate

Interventions

  • oral administration, 3 times/day

    Also known as: Mucosta® Tab.

  • oral administration, 3 times/day

    Also known as: Gasmotin® tab.

06

What researchers measure

Primary outcomes

  1. AUCτ,ss of Mosapirde citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  2. Cmax,ss of Mosapirde citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  3. AUCτ,ss of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  4. Cmax,ss of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

Secondary outcomes

  1. AUClast,ss of Mosapride citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  2. AUCinf,ss of Mosapride citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  3. Tmax,ss of Mosapride citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  4. t1/2 of Mosapride citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  5. Cmin,ss of Mosapride citrate 5mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  6. AUClast,ss of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  7. AUCinf,ss of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  8. Tmax,ss of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  9. t1/2 of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

  10. Cmin,ss of Rebamipide 100mg

    Time frame: D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose

07

Study locations

1 site
  • Yonsei University Health System, Severance Hospital
    Seoul, 120-752, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Jun 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Apr 8, 2014
Start
May 2013
Primary completionActual
Jun 2013
CompletionActual
Aug 2013
Last update
Apr 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02106130
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
May 2013
Primary completion
Jun 2013
Completion
Aug 2013
Last update
Apr 8, 2014

Study contacts

Chun-ok Kim, MD
principal investigator · Yonsei University Health System, Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rebamipide · Mosapride

Start the discussion